These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 30955120)
1. Efficacy and safety of intravitreal drug injections using a short 34-gauge needle. Sasajima H; Tsuboi K; Murotani K; Kamei M Jpn J Ophthalmol; 2019 May; 63(3):269-275. PubMed ID: 30955120 [TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A Retina; 2006; 26(9):999-1005. PubMed ID: 17151486 [TBL] [Abstract][Full Text] [Related]
3. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION. Lotfy A; Solaiman KAM; Abdelrahman A; Samir A Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552 [TBL] [Abstract][Full Text] [Related]
4. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Arevalo JF; Sanchez JG; Wu L; Maia M; Alezzandrini AA; Brito M; Bonafonte S; Lujan S; Diaz-Llopis M; Restrepo N; Rodríguez FJ; Udaondo-Mirete P; Ophthalmology; 2009 Aug; 116(8):1488-97, 1497.e1. PubMed ID: 19545900 [TBL] [Abstract][Full Text] [Related]
5. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration. Lee SJ; Koh HJ Ophthalmology; 2011 Jan; 118(1):101-10. PubMed ID: 20678805 [TBL] [Abstract][Full Text] [Related]
6. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Lazic R; Lukic M; Boras I; Draca N; Vlasic M; Gabric N; Tomic Z Retina; 2014 Apr; 34(4):719-24. PubMed ID: 23975006 [TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor. Kim KH; Kim JH; Chang YS; Lee TG; Kim JW; Lew YJ Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037 [TBL] [Abstract][Full Text] [Related]
8. Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up -- the SOLO study. Bezatis A; Spital G; Höhn F; Maier M; Clemens CR; Wachtlin J; Lehmann F; Hattenbach LO; Feltgen N; Meyer CH Acta Ophthalmol; 2013 Aug; 91(5):e340-7. PubMed ID: 23638803 [TBL] [Abstract][Full Text] [Related]
9. Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience. Blanc J; Deschasse C; Kodjikian L; Dot C; Bron AM; Creuzot-Garcher C Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1441-1448. PubMed ID: 29855706 [TBL] [Abstract][Full Text] [Related]
10. Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin(®) ). Algvere PV; Von Wendt G; Gudmundsson J; Seregard S; Kvanta A Acta Ophthalmol; 2010 Dec; 88(8):836-41. PubMed ID: 19900206 [TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of ziv-aflibercept in retinal diseases. Mansour AM; Ashraf M; Dedhia CJ; Charbaji A; Souka AAR; Chhablani J Br J Ophthalmol; 2017 Oct; 101(10):1374-1376. PubMed ID: 28270485 [TBL] [Abstract][Full Text] [Related]
13. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Ding X; Li J; Hu X; Yu S; Pan J; Tang S Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319 [TBL] [Abstract][Full Text] [Related]
14. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA; Retina; 2008; 28(10):1387-94. PubMed ID: 18827735 [TBL] [Abstract][Full Text] [Related]
15. One-year outcomes of less frequent bevacizumab in age-related macular degeneration. Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity. Kim M; Jeong S; Sagong M Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):691-697. PubMed ID: 27796671 [TBL] [Abstract][Full Text] [Related]
17. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure. Kim YJ; Sung KR; Lee KS; Joe SG; Lee JY; Kim JG; Yoon YH Am J Ophthalmol; 2014 Jun; 157(6):1266-1271.e1. PubMed ID: 24561173 [TBL] [Abstract][Full Text] [Related]
18. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes. Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625 [TBL] [Abstract][Full Text] [Related]
19. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration]. Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687 [TBL] [Abstract][Full Text] [Related]
20. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion. Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]